CIMZIA Solution for Injection
Certolizumab pegol
200 mg
Vetter Pharma-Fertigung GmbH & Co.KG
| Pack size | 2 Pre-filled Syringe (1 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 1419.70 AED |
Indications
CIMZIA Solution for Injection is used for:
Reducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA).
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Certolizumab pegol :
Mechanism of Action
Certolizumab pegol binds to free and membrane-bound human TNFa with a KD of 90pM and neutralizes its activity. Extent of neutralization is also dose-dependent. It also inhibited the release of lipopolysaccharide-induced IL-1A from monocytes. TNFa is a key pro-inflammatory cytokine with a central role in inflammatory processes in which elevated levels have been observed in patients with RA and Crohn's. Certolizumab pegol selectively neutralizes TNFa (IC90 of 4 ng/mL for inhibition of human TNFa in the in vitro L929 murine fibrosarcoma cytotoxicity assay). It does not bind to TNF-A. As certolizumab is only a Fab' fragment and thus missing the Fc region, it does not fix complement or cause antibody-dependent cell-mediated cytotoxicity. Furthermore, apoptosis of monocytes or lymphocytes, or neutrophil degranulation have not been observed in vitro.
Note
CIMZIA 200 mg Solution for Injection manufactured by Vetter Pharma-Fertigung GmbH & Co.KG. Its generic name is Certolizumab pegol. CIMZIA is availble in Saudi Arabia.
Farmaco SA drug index information on CIMZIA Solution for Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.